Background. Homo sapiens mature micro-ribonucleic acid (miRNA)-200b-3p and 200c-3p are predicted to bind to 3' untranslated region of mRNA encoding human cytomegalovirus (HCMV) immediate early protein 2 (IE2). We hypothesized that expression of these miRNAs pretransplant could predict HCMV replication after solid organ transplantation (SOT).
Human cytomegalovirus (HCMV) is an opportunistic pathogen that causes significant morbidity and potential mortality in solid organ transplantation (SOT) recipients [1] [2] [3] [4] [5] . The majority of HCMV infection after SOT is due to the replication of latent virus from immunosuppressive drugs [6] [7] [8] taken after transplantation. Immediate early protein 2 (IE2), encoded by the HCMV unique long region (UL)122-123, plays an essential role in initiating and regulating viral early gene activation, as well as propagating the subsequent steps of the HCMV lytic replication cycle [9] [10] [11] . These findings underscore the potential utility in targeting HCMV IE2 as a novel therapy aimed at preventing HCMV replication.
The replication of HCMV post-transplantation involves a complex interaction between the host immune response (both innate and adaptive), immunosuppressive drugs, and the virus. HCMV-specific T-cell responses have been shown to be important for controlling HCMV replication [12] . Another important aspect of host-pathogen interaction may be through the microribonucleic acid (miRNA) response. MiRNAs are small noncoding RNA molecules composed of [18] [19] [20] [21] [22] nucleotides that can alter the process of protein synthesis, mainly by suppressing gene expression via translational suppression. This process occurs when the mature miRNA (miR) binds the 3' untranslated region (UTR) of specific messenger RNA (mRNA) transcripts; the miRNA binding site on the mRNA transcript is termed the seed sequence [13, 14] . In silico analysis is capable of predicting which of the >2500 known miRNA molecules binds the 3' UTR of mRNA molecules that correspond to proteins of interest [15] . Several studies have suggested that the host miRNA response is capable of binding specific viral targets, thereby affecting viral replication [16] . However, there are less data on the biological significance of this response in a relevant clinical population.
The homo sapiens (hsp)-miRNA-200 family, with highly conserved seed sequences, is composed of 5 members divided into 2 clusters: hsp-miR-200a, -200b, and 429 are found at a locus on chromosome 1p36; and hsp-miR-200c and -141 are located on chromosome 12p13 [17] . The BiBiServe (Bielefeld BioInformatics Service) RNAhybrid algorithm tool predicts that hsp-miR-200b-3p, 200c3p, and -429 may bind the 3' UTR of mRNA that encodes HCMV IE2, and recent in vitro data has supported this prediction [18] (Supplementary Figure 1) . Based on this, we hypothesized that the host miRNA response may play a biologically relevant role in preventing HCMV replication post-transplant. To test this hypothesis, we evaluated whether the expression of hsp-miR-200b-3p, -200c-3p, or -429 in peripheral blood mononuclear cells (PBMCs) could predict HCMV replication in SOT recipients.
MATERIALS AND METHODS

Patient Cohort
PBMCs were collected from 272 SOT recipients prospectively enrolled in the Swiss Transplant Cohort Study (STCS) from May 2008 to March 2011. The details and unique features, including clinical data collection, for the STCS were previously described [19] [20] [21] [22] . For the current study, clinical data during the first year of follow-up were used. Characteristics of our cohort included the following: (1) baseline whole blood was drawn pretransplantation [21] , (2) HCMV donor + /recipient + (D + /R + ) or donor -/recipient + (D -/R + ) pretransplant serostatus was recorded, and (3) no patient received antiviral prophylaxis (preemptive monitoring strategy). The detailed protocol of the preemptive approach was previously described [22] . HCMV disease (which includes both viral syndrome and tissue-invasive disease) was defined according to international guidelines [22, 23] . HCMV replication was classified as asymptomatic HCMV viremia, or HCMV disease, either viral syndrome or tissue-invasive disease [23] .
PBMC Stimulation and miRNA Measurement
All PBMCs were collected pretransplant and samples were transferred for processing at a single center. PBMCs were separated using the density-gradient centrifugation method with Ficoll-Plaque media (Sigma-Aldrich, Oakville, ON). Next, 3 × 10 5 PBMCs were stimulated with HCMV Towne strain at a multiplicity of infection (MOI) of 0.03 for 24 hours in 1.5 mL complete Roswell Park Memorial Institute (RPMI)-1640 medium with 5% CO 2 at 37°C [24] . After stimulation, PBMCs were washed twice with phosphate-buffered saline and lysed using QIAzol lysis reagent (QIAGEN Inc, Toronto, ON), then 30 µL total RNA was eluted using an miRNeasy kit (QIAGEN Inc) according to the manufacturer's instructions. All RNA samples contained an RNA Integrity Number ≥7, as measured by fluorescent on-chip microfluidic capillary electrophoresis using the RNA 6000 Pico Assay kit (Agilent Technologies, Inc, Waldbronn, Germany) [25] [26] [27] . All RNA was stored at −80°C until needed.
Real-time Quantitative Reverse Transcription-Polymerase Chain Reaction
To quantify miRNA, we performed TaqMan MicroRNA real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for hsp-miRNA-200b-3p (Assay ID: 002251), hsp-miRNA-200c-3p (Assay ID: 002300), and hsp-miRNA-429 (Assay ID: 001024) (Life Technologies, Burlington, ON) as per manufacturer's instructions. Using 2 ng/µL total RNA, the reverse transcription (RT) reaction with stem-loop primers was performed in a thermal cycler (Eppendorf Matercycler EP Gradient S, New York) with the following cycling conditions: 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes. For the quantitative realtime polymerase chain reaction (PCR), we combined 1.33 µL of the RT product, 10 µL TaqMan Universal PCR master mix, forward and reverse primers, and nuclease-free water to bring the total volume to 20 µL per reaction. The reaction was completed using the StepOne Real-Time PCR System (ThermoFischer Scientific, Mississauga, ON) with the following cycling conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. To quantify, we used a standard curve consisting of mirVana miRNA mimics (Life Technologies) that corresponded to each of the 3 miRNAs of interest, ranging from 10 to 10 6 copies/µL per PCR test. We expressed the amount of each miRNA as copies per µL of input RNA. The limit of detection of the assay was 100 copies/µL of input RNA; anything under this threshold was considered as being zero for continuous variable analysis.
PBMC Culturing, Cell Lines, and Virus Strains
Primary PBMCs were maintained in RPMI-1640 (Life Technologies). Three cell lines were used in this study: human foreskin fibroblast-1 (HFF-1), Henrietta Lacks (HeLa), and the human fetal lung fibroblast cell line MRC-5 (ATCC, Gaithersburg, MD). Dulbecco's Modified Eagle's medium (Life Technologies) was used to maintain HFF-1, MRC-5, and HeLa cells. All complete growth media were supplemented with 10% heat-inactivated fetal bovine serum, 4.5 g/L glucose, 4 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 100 U/mL penicillin, and 100 µg/mL streptomycin (Sigma-Aldrich). Strains HCMV AD169 and Towne (ATCC) were propagated in MRC-5 cells and collected according to a previously published protocol [28] .
Transfection of miRNA Mimics and Plasmid DNA
A total of 3 × 10 4 HFF-1 cells were transfected with synthetic oligonucleotides of precursor miRNA (pre-miRNA) with a double-strand stem-loop structure, corresponding to the target miRNA and recombinant pmiRGLO plasmid DNA simultaneously, and mixed with Lipofectamine 3000 (Life Technologies) and Opti-MEM medium (Life Technologies), according to manufacturer's protocol. Transfections were performed at 80%-90% cell confluence. We used the mirVana (Ambion, Austin, TX) isolation kit for the miRNA negative control mimic (Life Technologies) as a negative control for transfection experiments. This mimic consists of a pre-miRNA with a double-stranded stem-loop structure, and is composed of a chemically modified random, scrambled sequence that has been extensively tested in human cell lines and validated to not produce any identifiable biological responses [29] . To evaluate the transfection efficiency, a mirVana miRNA-1 positive control mimic was used (Life Technologies), which has been shown to downregulate histone deacetylase 4 (HDAC4) expression [30] .
Immunoblotting
A total of 10 6 HFF-1 cells were seeded in 6-well plates. After overnight incubation, cells were infected with the HCMV AD169 strain at an MOI of 0.1. Next, cells were transfected with one of the miRNA mimics at 1 hour postinfection. To evaluate whether the delayed transfection of mimics after infection could change the expression of IE2, cells were infected and then transfected 1 dpi and 3 dpi. For mock experiments, we did not transfect the cells with miRNA mimics, but only added Lipofectamine RNAiMAX (Life Technologies). We collected total protein after cell lysis using radioimmunoprecipitation assay buffer (Bio-Rad Laboratories, Inc, CA) at 3 dpi and 7 dpi in experiments to evaluate the effectiveness of transfection 1 hour after infection and 3 days after transfection (delayed transfection), and stored the protein at −20°C.
Mouse antihuman primary monoclonal antibodies were used at 1:200 for the HCMV IE2 (pp86) (clone 12E2), 1:500 for β-actin (clone C4), and 1:100 for HDAC4 (clone D-1) detection, and the secondary antibody (goat antimouse immunoglobulin G-horseradish peroxidase) was used at 1:2000 (Santa Cruz Biotechnology, Inc, CA). We captured the chemiluminescent signal using a charge coupled device camera-based imager (MicroChemi, DNR Bio-Imaging Systems Ltd, Jerusalem, Israel). All experiments were completed in triplicate. We obtained the quantitative values for signal intensity in captured bands using Image J software (Center for Information Technology, NIH, Bethesda, MD).
Statistical Analysis
Statistical analysis was performed using SPSS V20.0 (SPSS Inc, Chicago, IL) and GraphPad Prism V6 (GraphPad Software, Inc, La Jolla, CA). Differences in categorical and continuous variables among groups were analyzed by χ 2 test and MannWhitney U test, respectively. To assess the independent predictive factors associated with the development of HCMV replication after SOT, we performed multivariate logistic regression analysis using all statistically significant variables with a P value ≤.05 obtained from univariate analyses. All P values were 2-tailed, and a P value ≤.05 was considered statistically significant.
RESULTS
Patient Clinical Characteristics
The basic clinical characteristics of all 272 patients are summarized in Table 1 . The majority of patients were kidney or liver transplant recipients (92%). HCMV replication developed in 144 (52.9%) recipients. The most common presentation of HCMV replication was asymptomatic viremia in 48.5% (132/272), followed by viral syndrome in 6.3% (17/272) and tissue-invasive disease in 3.7% (10/272). Thirty-nine (27.1%) of 144 patients experienced ≥2 episodes of HCMV replication. The median duration from first SOT to all episodes of first HCMV replication in all patients was 1.2 months (interquartile range, 0.9-2.2 months). Graft rejection in the HCMV replication group occurred with significantly higher frequency than in the group that did not develop HCMV replication (36.1% vs 24.2%; P = .036). Furthermore, HCMV replication was more common among individuals with a D + /R + serostatus compared to those with D -/R + serostatus (68.1% vs 31.9%; P = .045).
Expression Levels of miRNAs in PBMCs
Among all 272 SOT recipients, the median expression level Figure 1D ). When analyzed as a categorical variable (less than vs greater than 100 copies/µL), hsp-miR-200b-3p levels below the limit of detection were more common among SOT recipients that developed HCMV replication versus those that did not (34.0% vs 21.9%; P = .026), and in those that developed HCMV disease versus no disease (57.7% vs 25.2%; P < .001) ( Table 2 ). No differences were observed for hsp-miR-200c-3p and hspmiR-429. Expression of hsp-miR-200b-3p at ≥100 copies/µL was a significant independent predictive factor for HCMV replication after SOT, with consistent statistical values in 3 models of multivariate regression analysis (odds ratio, 0.53; 95% confidential interval, .30-.92; P = .02). Table 3 provides data for the multivariate model, including HCMV serostatus and graft rejection. Figure 4A ) and 7 dpi ( Figure 4B) , with 2.7-and 2.5-fold lower signal densities compared with mock-transfected cells, respectively. Transfection with hsp-miR-200c-3p 1 hour after infection did not result in significant changes to IE2 protein expression at 3 dpi, but induced a 1.5-fold lower signal density at 7 dpi in comparison. Next, we assessed the antiviral role of miRNA in targeting IE2 when cells were transfected 1 dpi or 3 dpi. With regard to cells infected and subsequently transfected at 1 dpi, we saw a significant decrease in IE2 expression among cells transfected with hsp-miR-200b-3p and -200c-3p, with the latter resulting in the greatest reduction in IE2 protein expression ( Figure 4C ). With respect to cells infected with HCMV and transfected with miRNA 3 dpi, IE2 protein levels were also lower among hsp-miR-200c-3p-transfected cells ( Figure 4D ), but to a lesser degree than when cells were transfected 1 hour postinfection. At both time points, the greatest reduction in IE2 protein expression occurred in cells transfected with hsp-miR-200c-3p. Cells transfected with 
DISCUSSION
Our study provides evidence that the host miRNA response to HCMV, specifically hsp-miR-200b-3p, could have a relevant biological role in controlling viral replication post-transplant. Control of HCMV replication may occur through suppression of the production of the HCMV IE2 protein, thereby directly inhibiting the replication of latent virus. We demonstrated that the ex vivo production of hspmiR-200b-3p in response to viral stimulation was associated with a lower incidence of asymptomatic HCMV replication and disease. This association remained significant in a multivariate model, controlling for other factors associated with HCMV replication. While the potential utility of a single miRNA measurement as a biomarker is unclear, this study provides a first proof-of-concept that miRNAs likely have biologically relevant effects post-transplant. Measurements of these and other miRNAs, possibly in conjunction with T-cell and other immunologic assessments, could be explored as potential biomarkers. The clinical data we present are supported by the in vitro validation of IE2 as a target of the miRNA 200 family and by previous work published by O'Connor and colleagues [18] .
Current strategies for the prevention of HCMV after transplantation rely on antiviral prophylaxis or regular viral load monitoring with subsequent preemptive antiviral therapy in Results for hsp-miR-200b-3p, hsp-miR-200c-3p, and hsp-miR-429 Firefly and Renilla luciferase were measured at 2 days after simultaneous transfection of both recombinant pmiRGLO plasmid and each miRNA mimic. The mirVana miRNA negative control mimic was used as negative control of miRNAs. The mock experiment was performed with only transfecting agents without any miRNA. Each experiment was done in triplicate. The upper line of each bar and error bar indicate the median and interquartile range, respectively. The P value in each mimic was obtained from the comparison with mock experiment. *P < .05; **P < .001. The materials and methods were described in Supplementary Material.Abbreviations: HCMV, human cytomegalovirus; hsp, homo sapiens; IE2, immediate early protein 2; miR, mature microRNA; miRNA, microRNA; mRNA, messenger RNA; RNA, ribonucleic acid; UTR, untranslated region.
patients with early evidence of replication. Antiviral prophylaxis is effective in HCMV disease prevention, but is costly and may result in significant toxicity. Similarly, preemptive strategies are effective but require frequent monitoring, and viral load thresholds for initiation of therapy are poorly defined. Recently, assessing the host immune response as a biomarker to predict HCMV replication and further refine prevention has gained significant interest. The most common parameters that have been evaluated include HCMVspecific T-cell responses [31] . Examples include interferon-γ release assays that measure HCMV-specific T-cell-mediated immunity such as QuantiFERON-CMV assay, as well as enzyme-linked immunospot assay, and intracellular cytokine staining using flow cytometry [4, 7, 32, 33] . For example, in a multicenter study evaluating the predictive value of CD8 + T-cell responses to HCMV, a total of 127 HCMV D + /Rpatients were assessed with serial CD8 + T-cell measurements using the QuantiFERON-CMV assay [12] . The incidence of symptomatic HCMV disease was significantly higher in patients with undetectable interferon-γ responses at the end of prophylaxis versus those with positive responses. In another study, CD4 + and regulatory T-cell responses in patients with early evidence of viral replication allowed for the prediction of spontaneous viral clearance versus progression [34] . The potential role of miRNAs as another regulatory layer that may affect HCMV replication represents an exciting and novel area of study. HCMV infection likely results in a Figure 4 . Expression of IE2 protein in various time intervals between HCMV infection and transfection of each miRNA. miRNA mimics were transfected 1 hour after HCMV infection, then proteins were extracted at 3 dpi (A) and 7 dpi (B). Each miRNA mimic was transfected 1 day (C) and 3 days (D) after HCMV infection, then proteins were extracted 3 days post-transfection. The mock experiment was performed with only transfecting agents without any miRNA. The mirVana miRNA negative control mimic was used as scrambled oligonucleotide for negative control of miRNAs. The upper line of each bar and error bar indicate the median and interquartile ranges, respectively. The P value in each mimic was obtained from the comparison with mock experiment. *P < .05; **P < .001. Abbreviations: dpi, days postinfection; HCMV, human cytomegalovirus; IE2, immediate early protein 2; miRNA, microRNA; MOI, multiplicity of infection; NC, negative control; RNA, ribonucleic acid.
complex host miRNA response that may influence viral replication. For example, using high-throughput sequencing, Fu and colleagues [35] evaluated host miRNA expression in a model of latent HCMV infection. They found 49 cellular miRNAs that were differentially expressed. Functional annotation of the target genes suggested that most were involved in endocytosis, as well as in certain signaling pathways. The miR-200 family was not among the 49 differentially expressed ones, but this may be due to differences in the model used, including the specific lab-adapted strain of HCMV (Toledo strain in a monocytic cell line). In a study by Zawislak and colleagues [36] , murine CMV infection resulted in an upregulation of miR-155, which in turn, affected distinct stages of natural killer cell activation and homeostasis.
There are minimal data on miRNAs and HCMV in the transplant setting. Egli and colleagues [16] used miRNA microarray data from PBMCs of transplant recipients with and without HCMV viremia, and showed that 142 of 847 hsp-miRNAs were differentially expressed between the 2 patient groups. Based on further in vitro analysis, a subset of miRNAs was then evaluated in a cohort of 242 transplant patients with active HCMV viremia. Significant dynamic changes of some miRNAs were observed coincident with antiviral therapy, although no clear predictive biomarkers were observed. Again, the miR-200 family was not among those found to be differentially expressed. Methodical differences (stimulated vs unstimulated PBMCs, microarray method vs real-time PCR) and assessment at a post-transplant versus pretransplant time point may account for some of these differences. Gambarino and colleagues [37] evaluated hsp-miR146a expression in 22 kidney transplant recipients with high, low, and negative HCMV viral loads and found no association between expression level and viral replication. Another layer of complexity involves viral production of miRNAs. For example, detection of hcmv-miR-UL22A-5p in the whole blood of transplant recipients has been associated with the recurrence of HCMV viremia after discontinuation of therapy [38] .
The role of the miR-200 family in HCMV following transplant is particularly interesting. Based on seed sequences of the miRNA family (Supplementary Figure 1) , 3 members are predicted to bind to the 3' UTR of HCMV UL122 (hspmiR-200b-3p, 200c-3p, and -429). O'Conner and colleagues [18] demonstrated that miR-200 family members target the UL122 (IE2) protein of HCMV using a combination of in vitro validation methods. These included using luciferase reporter assays, as well as demonstrating that the overexpression of miR-200 family miRNAs in fibroblasts resulted in decreased viral titers. They found higher levels of miR-200 family member miRNAs in monocytes (associated with HCMV latency) as compared to cells permissive for lytic infection, such as macrophages. Our in vitro data support that hsp-miR-200b-3p is capable of targeting IE2 and downregulating its expression. Previously, O'Connor and colleagues [18] evaluated the change of IE2 protein levels at the early time intervals of 6 and 9 hours postinfection. In contrast to the study by O'Connor et al., we measured IE2 expression at 3 dpi and 7 dpi, and furthermore evaluated the in vitro suppressive effect of hsp-miR-200b-3p and -200c-3p when administered 1 hour postinfection, as well as 1 dpi or 3 dpi. Interestingly, both hsp-miR-200b-3p and hsp-miR200c-3p were still able to decrease IE2 expression.
Limitations of the study include small number of recipients who experienced HCMV disease. In addition, only a single time point pretransplant was evaluated. To look at the dynamic changes in miRNA, assessments of further post-transplant samples may be useful. Quantitative viral load data were not available for this cohort, in part due to differences in viral load assays across centers. An analysis of viral load versus miRNA levels would provide further useful data. In addition, we assessed miRNA response in PBMCs after stimulation with live virus. The optimal stimulant in this setting is unknown, but live virus may reflect the most accurate physiologic stimulus. Another approach may be to assess basal levels of miRNA in the absence of specific ex vivo stimulation. Finally, the absolute log-difference in miRNA expression level between patients with and without HCMV (approximately 0.5 log 10 -difference, or about 3-fold) was modest, but we believe is within the range of reproducibility of the assay. For each sample, steps were taken to ensure high RNA integrity of the input sample. In addition, the stem-loop PCR design used in our assay contributed enhanced sensitivity and specificity of detection, providing us with more confidence in the validity of the findings.
Strengths of our study include the large sample size, and the lack of antiviral prophylaxis in this cohort of patients, which allows a real assessment of the impact of miRNA responses on the development of HCMV replication. Our findings need to be evaluated in various clinical settings, including high-risk groups for HCMV infection such as D + /R -SOT recipients. In addition, miRNA expression may be assessed in different types of samples such as bronchoalveolar lavage fluid for lung transplant recipients and urine for kidney transplant recipients.
In conclusion, our study suggests that miRNA responses may play a biologically relevant role in controlling HCMV replication after transplantation. Exploring their role as biomarkers or therapeutic targets may open new avenues to prevent and treat replication of HCMV.
